Dual function of RGD-modified VEGI-192 for breast cancer treatment

Bioconjugate Chemistry

Volumn 23, Issue 4, 2012, Pages 796-804

  Wu, Jueheng ^a   Jiang, Yi ^a,c   Yang, Wan ^b   He, Zhenjian ^a   Meng, Shiyu ^b   Zhang, Qianhui ^b   Lin, Min ^b   Zhang, Henan ^b   Li, Weifeng ^b   Yang, Yaochao ^b   Jia, Yiqun ^b   Qian, Liang ^b   Lu, Dihan ^b   Cai, Wenjia ^b   Luo, Guotian ^b   Wang, Yesong ^a   Zhu, Xun ^a   Li, Mengfeng ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c ZIGONG FIRST PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; CELL DEATH; CELL ENGINEERING; CELL SIGNALING; DISEASE CONTROL; DISEASES; ENDOTHELIAL CELLS; RECOMBINANT PROTEINS; TUMORS;

ANGIOGENESIS; ANGIOGENESIS INHIBITORS; ATTRACTIVE STRATEGIES; BREAST CANCER TREATMENT; DUAL FUNCTION; FUSION PROTEINS; GROWTH INHIBITOR; IN-VITRO; IN-VIVO; VASCULAR ENDOTHELIAL GROWTH;

CHEMICAL ACTIVATION;

CASPASE 3; CASPASE 8; HYBRID PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; PUMA PROTEIN; UNCLASSIFIED DRUG; VEGI 192 FUSION PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CELL ADHESION; CELL GROWTH; CELL SPREADING; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIUM; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; SIGNAL TRANSDUCTION; TUMOR CELL; UPREGULATION; VASCULARIZATION;

EID: 84860002953     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc2006576     Document Type: Article

References (29)

1. Folkman, J. (2006) Angiogenesis. Annu. Rev. Med. 57, 1-18.
2. Folkman, J. (1971) Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-6.
3. Tan, K. B., Harrop, J., Reddy, M., Young, P., Terrett, J., Emery, J., Moore, G., and Truneh, A. (1997) Characterization of a novel TNFlike ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene 204, 35-46. (Pubitemid 28022168)
4. Zhai, Y., Ni, J., Jiang, G. W., Lu, J., Xing, L., Lincoln, C., Carter, K. C., Janat, F., Kozak, D., Xu, S., Rojas, L., Aggarwal, B. B., Ruben, S., Li, L. Y., Gentz, R., and Yu, G. L. (1999) VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. Faseb J. 13, 181-9. (Pubitemid 29038287)
5. Zhai, Y., Yu, J., Iruela-Arispe, L., Huang, W. Q., Wang, Z., Hayes, A. J., Lu, J., Jiang, G., Rojas, L., Lippman, M. E., Ni, J., Yu, G. L., and Li, L. Y. (1999) Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily. Int. J. Cancer 82, 131-136. (Pubitemid 29266118)
6. Yu, J., Tian, S., Metheny-Barlow, L., Chew, L. J., Hayes, A. J., Pan, H., Yu, G. L., and Li, L. Y. (2001) Modulation of endothelial cell growth arrest and apoptosis by vascular endothelial growth inhibitor. Circ. Res. 89, 1161-7. (Pubitemid 34627874)
7. Chew, L. J., Pan, H., Yu, J., Tian, S., Huang, W. Q., Zhang, J. Y., Pang, S., and Li, L. Y. (2002) A novel secreted splice variant of vascular endothelial cell growth inhibitor. Faseb J. 16, 742-4.
8. Hou, W., Medynski, D., Wu, S., Lin, X., and Li, L. Y. (2005) VEGI-192, a new isoform of TNFSF15, specifically eliminates tumor vascular endothelial cells and suppresses tumor growth. Clin. Cancer Res. 11, 5595-602. (Pubitemid 41060838)
9. Migone, T. S., Zhang, J., Luo, X., Zhuang, L., Chen, C., Hu, B., Hong, J. S., Perry, J. W., Chen, S. F., Zhou, J. X., Cho, Y. H., Ullrich, S., Kanakaraj, P., Carrell, J., Boyd, E., Olsen, H. S., Hu, G., Pukac, L., Liu, D., Ni, J., Kim, S., Gentz, R., Feng, P., Moore, P. A., Ruben, S. M., and Wei, P. (2002) TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 16, 479-92. (Pubitemid 34260924)
10. Bamias, G., Martin, C. 3rd, Marini, M., Hoang, S., Mishina, M., Ross, W. G., Sachedina, M. A., Friel, C. M., Mize, J., Bickston, S. J., Pizarro, T. T., Wei, P., and Cominelli, F. (2003) Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J. Immunol. 171, 4868-74. (Pubitemid 37310609)
11. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-85. (Pubitemid 28015876)
12. Chen, X., Wu, J., Liu, H., He, Z., Gu, M., Wang, N., Ma, J., Hu, J., Xia, L., He, H., Yuan, J., Li, J., Li, L., Li, M., and Zhu, X. (2010) Approaches to efficient production of recombinant angiogenesis inhibitor rhVEGI-192 and characterization of its structure and antiangiogenic function. Protein Sci. 19, 449-57.
13. Ruoslahti, E. (1996) RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol. 12, 697-715.
14. Pasqualini, R., Koivunen, E., and Ruoslahti, E. (1997) Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat. Biotechnol. 15, 542-6. (Pubitemid 27251571)
15. Brooks, P. C., Clark, R. A., and Cheresh, D. A. (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264, 569-71.
16. Meyer, A., Auernheimer, J., Modlinger, A., and Kessler, H. (2006) Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr. Pharm. Des. 12, 2723-47. (Pubitemid 44184633)
17. Ginsberg, M. H., Partridge, A., and Shattil, S. J. (2005) Integrin regulation. Curr. Opin. Cell Biol. 17, 509-16. (Pubitemid 41267165)
18. Curnis, F., Gasparri, A., Sacchi, A., Longhi, R., and Corti, A. (2004) Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity. Cancer Res. 64, 565-71. (Pubitemid 38120895)
19. Li, J., Ji, J., Holmes, L. M., Burgin, K. E., Barton, L. B., Yu, X., Wagner, T. E., and Wei, Y. (2004) Fusion protein from RGD peptide and Fc fragment of mouse immunoglobulin G inhibits angiogenesis in tumor. Cancer Gene Ther. 11, 363-70. (Pubitemid 38586092)
20. Li, S., Wei, J., Yuan, L., Sun, H., Liu, Y., Zhang, Y., Li, J., and Liu, X. (2011) RGD-modified endostatin peptide 30 derived from endostatin suppresses invasion and migration of HepG2 cells through the alphavbeta3 pathway. Cancer Biother. Radiopharm.
21. Jing, Y., Lu, H., Wu, K., Subramanian, I. V., and Ramakrishnan, S. (2011) Inhibition of ovarian cancer by RGD-P125A-endostatin-Fc fusion proteins. Int. J. Cancer 129, 751-61.
22. Arap, W., Pasqualini, R., and Ruoslahti, E. (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279, 377-80. (Pubitemid 28063372)
23. Ellerby, H. M., Arap, W., Ellerby, L. M., Kain, R., Andrusiak, R., Rio, G. D., Krajewski, S., Lombardo, C. R., Rao, R., Ruoslahti, E., Bredesen, D. E., and Pasqualini, R. (1999) Anti-cancer activity of targeted pro-apoptotic peptides. Nat. Med. 5, 1032-8. (Pubitemid 29439574)
24. Zitzmann, S., Ehemann, V., and Schwab, M. (2002) Arginineglycine- aspartic acid (RGD)-peptide binds to both tumor and tumorendothelial cells in vivo. Cancer Res. 62, 5139-43. (Pubitemid 35024582)
25. Wen, L., Zhuang, L., Luo, X., and Wei, P. (2003) TL1A-induced NF-kappaB activation and c-IAP2 production prevent DR3-mediated apoptosis in TF-1 cells. J. Biol. Chem. 278, 39251-8. (Pubitemid 37221829)
26. Xie, G., Zhu, X., Li, Q., Gu, M., He, Z., Wu, J., Li, J., Lin, Y., Li, M., She, Z., and Yuan, J. (2010) SZ-685C, a marine anthraquinone, is a potent inducer of apoptosis with anticancer activity by suppression of the Akt/FOXO pathway. Br. J. Pharmacol. 159, 689-97.
27. Palmieri, D., Lee, J. W., Juliano, R. L., and Church, F. C. (2002) Plasminogen activator inhibitor-1 and -3 increase cell adhesion and motility of MDA-MB-435 breast cancer cells. J. Biol. Chem. 277, 40950-7. (Pubitemid 35215683)
28. Zilberberg, L., Shinkaruk, S., Lequin, O., Rousseau, B., Hagedorn, M., Costa, F., Caronzolo, D., Balke, M., Canron, X., Convert, O., Lain, G., Gionnet, K., Goncalves, M., Bayle, M., Bello, L., Chassaing, G., Deleris, G., and Bikfalvi, A. (2003) Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth inhibitor. J. Biol. Chem. 278, 35564-73. (Pubitemid 37102329)
29. Haier, J., Goldmann, U., Hotz, B., Runkel, N., and Keilholz, U. (2002) Inhibition of tumor progression and neoangiogenesis using cyclic RGD-peptides in a chemically induced colon carcinoma in rats. Clin. Exp. Metastasis 19, 665-72. (Pubitemid 36092261)